DeepNews
$CMPS (COMPASS Pathways plc) COMPASS Pathways: Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression London, UK and New York, US, 19 January 2022 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health www.finanznachrichten.de/nachrichten-2022-01/55012136-compass-pathways-two-thirds-of-physicians-surveyed-believe-psilocybin-therapy-has-potential-benefit-for-patients-with-treatment-resistant-depression-399.htm
Like CommentShare
null
.